

RSV and Rhinovirus asymptomatic upper airway infection increases pneumococcal carriage acquisition rates and density in adults whereas nasal inflammation is associated with bacterial shedding.

Elena Mitsi^{1,2}, Elissavet Nikolaou^{2,3}, Andre Goncalves^{1,2}, Annie Blizard², Helen Hill², Madlen Farrar², Angela Hyder-Wright², Ashleigh Howard², Filora Elterish¹, Carla Solorzano^{1,2}, Ryan Robinson², Jesus Reine^{1,2}, Andrea M. Collins², Stephen B. Gordon^{2,4}, Jeffrey N. Weiser⁵, Debby Bogaert^{6,7}, Daniela M. Ferreira^{1,2}.

Authors and affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK

² Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK

³ Murdoch Children's Research Institute, *Melbourne*, Australia

⁴ Malawi Liverpool Wellcome-Trust Programme, Blantyre, Malawi

⁵ Department of Microbiology, New York University School of Medicine, New York, USA

⁶ Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

⁷ Department of Paediatric Immunology and Infectious Diseases, Utrecht, The Netherlands

Corresponding authors: daniela.ferreira@paediatrics.ox.ac.uk, elena.mitsi@paediatrics.ox.ac.uk

Key words: RSV, Rhinovirus, pneumococcal carriage, bacterial shedding, co-infection, nasal inflammation

ABSTRACT

Nasopharyngeal pneumococcal colonisation is a necessary step for disease development and the primary reservoir of bacterial spread and transmission. Most epidemiological studies report the impact of co-infection with respiratory viruses upon disease rates and outcome, but their effect on pneumococcal carriage acquisition and bacterial load is scarcely described. Here, we used controlled human infection with pneumococcus to assess whether certain respiratory viruses alter susceptibility to pneumococcal colonisation and bacterial density. A total of 581 healthy adults were screened for presence of upper respiratory tract viral infection before intranasal pneumococcal challenge. We showed that RSV and Rhinovirus asymptomatic infection conferred a substantial increase in carriage rates (88% and 66% of colonised individuals in Rhinovirus and RSV infected groups, respectively, vs 49% in the virus negative group). The risk ratio of pneumococcal colonization in RSV infected group was 5.3 (95% CI: 0.90 – 30.61, $p = 0.034$) and 2.03 (95% CI: 1.09-3.80, $p = 0.035$) in rhinovirus infected group. Pneumococcal density was overall greater in virus positive subjects, although RSV infection alone had a major impact on pneumococcal density up to 9 days post challenge, with a substantial 2-log increase at D2 compared to virus negative group (median, SEM: 3.76 ± 0.65 vs 1.79 ± 0.09) ($p = 0.02$). We also studied rates and kinetics of bacterial shedding through the nose and oral route in a subset of challenged individuals. Nasal bacterial shedding was twice more frequent than cough-induced shedding (64% vs 32%, respectively). High levels of bacterial colonisation density and nasal inflammation was strongly correlated with increased odds of nasal shedding, as opposed to cough-shedding.

Healthy adults can act as reservoir of transmission for pneumococcus, particularly when colonised with high density and have local inflammation, two key characteristics of pneumococcal colonisation in paediatrics and/or viral co-infection. Hence, vaccines targeting these respiratory pathogens have the dual potential of reducing transmission and disease burden due to their indirect benefit to off target pathogens.

1 INTRODUCTION

2 *Streptococcus pneumoniae* (the pneumococcus) is a leading opportunistic pathogen of the human
3 respiratory tract. Nasopharyngeal pneumococcal colonisation is a common event, with 40-90%
4 prevalence in young children (<5 years old) and 10-20% in adults in epidemiological studies [1-4].
5 Although colonisation of the nasopharynx is generally considered asymptomatic (the carrier state),
6 and young children experience multiple colonisation episodes, mostly without incident, under
7 certain circumstances pneumococci can invade sites and spread within the host, resulting in disease
8 development[5-7]. This paradox suggests that other factors beyond nasopharyngeal carriage play an
9 important role in the pathogenesis of pneumococcal disease [8, 9].

10 Viral infections, mainly respiratory syncytial virus (RSV) and influenza, seem to increase substantially
11 the risk of secondary pneumococcal infection, including invasive pneumococcal disease (IPD) [10,
12 11]. Epidemiological, clinical and experimental evidence suggest that these viruses increase bacterial
13 virulence and worsening disease outcome [12, 13], implying that non-invasive pneumococcal
14 serotypes possibly require enhancement by respiratory viruses to cause secondary bacterial
15 infection.

16 Colonisation is also the primary source and reservoir of pneumococcal transmission [6]. It is
17 postulated that a colonised person can shed bacteria via nasal secretion and mucosalivary fluid in
18 the form of droplets [14]. Colonisation and transmission are most common among young children,
19 especially in crowded settings, such as day care centres [15], or in association with episodes of viral
20 upper respiratory tract infection [16-18]. In animal models, higher density of colonising bacteria and
21 increased nasal secretions triggered by influenza, leads to increased bacterial shedding [19]. In
22 humans, influenza infection induced by Live attenuated influenza vaccine can trigger acute nasal
23 inflammation [20] and lead to higher density of colonising pneumococci [20, 21]. In children, viral
24 rhinitis has also been associated with elevated pneumococcal colonising density in children [22].

25 Here we studied the relationship between certain respiratory viruses and predisposition to
26 pneumococcal colonisation using a controlled human infection model with pneumococcus in adults.
27 As the onset of colonisation is known, it ascertains pathogen order and causality on bacterial density
28 and host responses.

29 In addition, we described the kinetics of bacterial shedding during early and later stages of
30 colonisation and provided first evidence that adults can also act as reservoir of bacterial spread
31 while they are colonised with *S. pneumoniae*.

32 METHODS

33 **Study design and sample collection**

34 A total of 581 healthy adults (aged 18-55 years), who participated in experimental human
35 pneumococcal challenge studies in the Liverpool School of Tropical Medicine, UK, between
36 November 2011 and October 2019, were challenged intranasally with live pneumococci serotype 6B,
37 as previously described [23]. All studies were approved by North-West National Health Service
38 Research Ethics Committee and participants gave informed consent. All participants were non-
39 smoking adults who had no close contact with at-risk individuals, such as young children (under the
40 age of 5 years) and the elderly (over 65 years with comorbidities). The median age of the subjects
41 was 21 (IQR:19-22) and 60% were female (351/581) (Table 1).

42 Nasal wash samples were collected before the intranasal inoculation (screening visit) and at several
43 time points post inoculation, whereas oropharyngeal swabs were collected only at baseline. For a
44 subset of participants, nasal lining fluid (using Nasosorption™ filters) and nasal cells (using Rhino-Pro
45 cures) were collected at baseline and on days 2, 7 and 16 after challenge. Also, shedding samples,
46 such as cough plates and nose-to-hand (NtH) swabs were collected for a subset of participants on
47 days 2, 6, 16 and 22 after inoculation with pneumococcus serotype 6B.

48 **Pneumococcal colonisation and bacterial shedding**

49 Pneumococcal detection was performed in NW samples by classic microbiology methods, as
50 previously described[23, 24]. Participants in whom experimental pneumococci were detected in NW
51 samples at any visit post inoculation were defined as experimentally colonised.

52 To study bacterial shedding during experimental colonisation, we implemented sampling
53 methodologies, such as cough plate method and nose-to-hand swabbing, which allowed us to
54 evaluate longitudinally bacterial shedding from the oral and nasal route, respectively
55 (Supplementary Fig.1). Post inoculation (at D2, D6, D14, D16 and D22) participants were asked to a)
56 cough twice on a blood agar plate enriched with 4 µg/ml gentamicin (Sigma, UK) and b) rub their
57 nose using the anatomical snuff box of their hands. Then, the snuff box area was swabbed using a
58 sterile cotton swab, following storage in STGG until sample processing. Both types of shedding
59 samples were collected before nasal wash or nasosorption samples collection to avoid artificial
60 induction and pneumococcal shedding was determined by classical microbiology methods in real
61 time. The cough plates were incubated immediately at 37°C with 5% CO₂ for 24 hours. The NtH
62 swabs were streaked out on a blood agar plate and an additional 20ul of the collected sample in
63 STGG was plated on a separate plate enriched with gentamicin (Sigma, UK) and incubated overnight
64 at 37°C with 5% CO₂. Following incubation, all the plates were inspected for presence of

65 pneumococci and pneumococcal phenotype identification. Serotype was confirmed by latex
66 agglutination. NtH samples were also tested for presence of pneumococcal DNA by a sequential
67 single-plex quantitative PCR (qPCR) using primers for *lytA* gene and *cpr* gene, specific for serotypes
68 6A/B, as previously published [25-27].

69 **DNA/RNA extraction and viral qPCR**

70 Nucleic acids for viral qPCR were extracted from one aliquot of 250 µL oropharyngeal swab and/or
71 150 µL of a paired nasal wash sample collected at baseline (5 days before inoculation) using the
72 Purelink™ Viral RNA/DNA Mini Kit (Life Technologies Corporation, Carlsbad, CA, USA) according to
73 the manufacturer's instructions. We tested for a broad panel of respiratory viruses using primers,
74 probes and PCR assay conditions specific for adenoviruses, parainfluenza virus 1–4, human
75 bocavirus, human coronavirus OC43, NL63 and 229E, respiratory syncytial virus (A and B), human
76 metapneumovirus, human rhinoviruses, enteroviruses and human influenza virus A and B, as
77 previously described [28].

78 **Cytokines analysis in nasal lining fluid**

79 Human nasal cytokines and chemokines were quantified in nasal wash supernatant using a
80 customised cytokine storm Olink Flex 21 target panel (TNFα, IL1a, IL1b, IL6, IL8, IL2, IFNγ, IFNα2,
81 IFNβ1, IFNλ1, IL12, granzyme A, IP-10, MIG, MCP-1, MIP-1a, MIP-1b, GM-CSF, IL33, IL4, IL10) from
82 Olink (Uppsala, Sweden) or a 30-Plex Human Cytokine Magnetic Luminex Kit (Thermo Fisher
83 Scientific), as previously described [20]. On the Olink platform the target protein bound to the
84 double oligonucleotide-labelled antibody probe with high specificity, and then a microfluidic real-
85 time PCR amplification of the oligonucleotide sequence was used to quantitatively detect the
86 resulting DNA sequence. The resulting threshold cycle (Ct)-data were processed for quality control
87 and normalized, using internal and external controls. On the Luminex platform, NW samples were
88 analysed on a LX200 (Bio-Rad) with xPonent3.1 software (Luminex Corp) following the
89 manufacturer's instructions. All samples were run in duplicate, and standards were run on all plates.
90 Calibration and verification beads were run prior to all runs. All cytokines' data (both Olink and
91 Luminex panel) were expressed in pg/ml.

92 **Nasal cell collection and immunophenotyping**

93 Nasal microbiopsies were collected by nasal curettage (Rhino-pro®, Arlington Scientific), as
94 described previously [29]. Two curette samples were collected into PBS + 5mM EDTA and 0.5% heat
95 inactivated FBS for immunophenotyping and an additional two curette samples were collected into
96 RLT (Qiagen) and stored at -80 for transcriptome analysis. In the microbiopses, nasal epithelial cells

97 and immune cells were stained with LIVE/DEAD® Fixable Violet Dead Cell Stain (ThermoFisher),
98 followed by a monoclonal antibody cocktail (Supplementary Table 1). Samples were acquired on a
99 LSR II cytometer (BD Biosciences) and analysed using Flowjo software version 10 (Treestar).
100 Compensation matrices were set using compensation beads (BD Biosciences and ThermoFisher).
101 Samples with less than 500 CD45+ leukocytes or 250 EpCam+ epithelial cells were excluded from
102 analysis. To adjust for the variability of cells collected within and between study participants,
103 absolute cell counts of the target populations were normalized with the absolute number of
104 epithelial cells. The gating strategy is shown in Supplementary Fig. 1.

105 **Nasal Cell RNA Sequencing and Bioinformatic Analysis**

106 *RNA sequencing:* Nasal cells were collected in RLT (QIAGEN) and stored at -80°C until extraction. RNA
107 extraction (RNeasy; QIAGEN), sample integrity assessment (Bioanalyzer; Agilent 2100), library
108 preparation and RNA sequencing (BGISEQ-500RS) were performed at the Beijing Genome Institute.
109 *RNA mapping and annotation:* Quality control of raw sequencing data was conducted using the
110 FastQC tool. The human reference genome assembly GRCh38 was mapped using STAR 2.5.0a [30].
111 Read counts from binary alignment map (BAM) files were obtained using featureCounts [31] utilizing
112 a general transfer format (GTF) gene annotation from the Ensembl database [32]. The
113 R/Bioconductor package DESeq2 (version 1.34.0) was used for identifying differentially expressed
114 genes, excluding features absent in more than 75% of samples[33].

115 *Functional analysis:* Gene Set Enrichment Analysis (GSEA) was conducted to identify significant
116 pathways in the ranked transcriptome (\log_2 fold-change multiplied by $-\log_{10}$ p-values), independent
117 of the differential expression cut-off [34], using the R package fgsea (version 1.20.0) [35]. Pathways
118 with a p-value < 0.05 and an enrichment of at least five genes were considered statistically
119 significant. The Reactome database (release 79) and Pathway Browser (version 3.750) were used for
120 this analysis [36]. Heatmap plots were generated using the R package pheatmap (version 1.0.12).

121 **Statistical analysis and Correlation plots**

122 Participant characteristics were summarised as n, median (interquartile range) or frequency
123 (percentage). Chi-squared test and Fisher's exact test were conducted to identify any significant
124 changes in categorical variables. Non-parametric Wilcoxon paired tests and Mann-Whitney tests
125 were conducted to compare quantitative data within the same group or between two groups,
126 respectively. In addition, Kruskal-Wallis rank-sum test with Dunn's correction were performed to
127 compare quantitative data amongst groups (three groups comparison). Tests were two-sided with
128 an α level of 0.05. For correlations, two-tailed Pearson's or Spearman's r test was used. To explore
129 the association between time after infection and vaccination, we employed a linear regression

130 model. Data were analysed in R software version 4.0.3 (R Foundation for Statistical Computing,
131 Vienna, Austria), using rstatix package (version 4.2.3) or in Graphpad Prism version 9.0.

132 Correlograms plotting the Spearman rank correlation coefficient (r), between all parameter pairs
133 were created with the corrplot package (v0.84) running under R (v3.6.1) in R studio (1.1.456).
134 Clustering of parameters was performed using the 'hclust' option of corrMatOrder. Spearman rank
135 two-tailed P values were calculated using corr.test (psych v1.8.12) and graphed (ggplot2 v3.1.1)
136 based on * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

137

138 RESULTS

139 **Asymptomatic viral infection of the upper airways with RSV and rhinovirus predisposes to** 140 **pneumococcal carriage acquisition.**

141 Cross-sectional analysis of naso/oropharyngeal samples collected from healthy adults in the UK
142 revealed that 17% (99/581) of the individuals were asymptotically infected with a respiratory
143 virus before pneumococcal challenge (Figure 1A). These asymptomatic URTIs were more frequent
144 during autumn and winter months (October – January) (Suppl. Figure 3A). Only infections caused by
145 single virus were detected, with rhinovirus (RH) being the most frequent (7.6%), followed by
146 seasonal coronaviruses (hCoV, 4%), whereas RSV-A/RSV-B, parainfluenza viruses (PIVs) and
147 adenovirus were less frequently detected (Figure 1A and Table 1), possibly as they are frequently
148 symptomatic and therefore participants would have been excluded prior to enrolment.

149 Experimentally induced pneumococcal colonisation was detected in 291 out of the 581 participants
150 (50%), as assessed by longitudinal analysis of the nasal wash samples post challenge and was more
151 common among female participants (56% female vs 41% male, $p=0.009$), as reported previously
152 [37]. Analysis of the asymptomatic URT cases based on carriage outcome (Spn-colonised and non-
153 colonised group) showed a differential distribution of respiratory viruses between the two groups.
154 RH, RSV and PIV were more apparent in those that become colonised after challenge (Figure 1C)
155 compared to those who remained non-colonised (Figure 1B). In presence of any respiratory virus in
156 the naso/oropharynx prior to challenge, pneumococcal carriage increased from 49% (235 out of 482
157 virus-negative individuals) to 57% (56 out of 99 virus-positive individuals) (Figure 1D). Assessment of
158 the effect of individual viral species on carriage acquisition revealed that URTI with certain viruses,
159 such as rhinovirus and RSV, likely PIVs but not HCoVs predispose individuals to pneumococcal
160 colonisation (Figure 1E). RH-, RSV- and PIV-infected groups reached colonisation rates of 66% (29/44,
161 $p=0.035$), 88% (7/8, $p=0.035$) and 71% (5/7, $p=0.26$), respectively, compared to 49% observed in the

162 virus negative group. The risk ratio of pneumococcal colonization was 2.03 (95% CI: 1.09-3.80, p=
163 0.035) in the RH infected group, 5.3 (95% CI: 0.90 – 30.61, p = 0.034) in the RSV infected group and
164 2.63 (95% CI: 0.56 – 13.3, p=0.26) in the PIV infected group (Table 2).

165 We also investigated whether URT viral infection influences the pneumococcal colonising density.
166 The area under the curve (AUC) of pneumococcal colonising density was significantly higher in the
167 virus positive compared to the virus negative group for the Day 2 to Day 7 [median, IQR: 13.38 (5.82-
168 20.21) vs 8.47 (5.2-14.15), p=0.007] and Day2 to Day14 interval post challenge [33.12 (16.25-42.16)
169 vs 20.40 (11.01-30.11), p=0.008] (Figure 1F). Comparison of colonisation density kinetics up to D21
170 post challenge between virus negative individuals and those infected with HCoV, Rhinovirus or RSV
171 suggested that the presence of any respiratory virus can have a transient effect towards increased
172 bacterial density (Figure 2G-I). Amongst different viruses, presence of RSV in the nasopharynx had
173 the most striking effect, as increased pneumococcal density by 2-log at D2 compared to virus
174 negative group (median, SEM: 3.76 ± 0.65 vs 1.79 ± 0.09) (p= 0.02) an observation that continued up
175 to D9 post challenge (Figure 2H). We also observed that seasonality affected colonising density in
176 the viral infected group. Increased prevalence of viral URTI in Autumn and Winter months was
177 followed by an increased in pneumococcal density during the same period of the year (Suppl. Figure
178 1B).

179

180 **Distinct nasal inflammatory profile in those with asymptomatic URT infection**

181 Levels of nasal inflammation induced by viral infection were assessed by measuring 33 cytokines in
182 the nasal wash samples collected before exposure to pneumococcus (screening). Individuals were
183 divided in three groups based on the type of viral infection (HCoV, RH, RSV) and compared to the
184 non-infected group (virus negative group) (Figure 2). Infection with RH, even in absence of
185 symptoms, elicited an acute nasal inflammatory response, with strong induction of pro-
186 inflammatory mediators (TNFa, IL6 and IL1b), monocyte recruiting chemokines (MIP-1a, MIP-1b) and
187 substantial increase in several antiviral mediators, such as type I, II and III interferons, granzyme A,
188 IP10 and MIG. Asymptomatic infection with seasonal coronaviruses (alpha- or beta-coronavirus)
189 induced a similar type of nasal inflammation compared to RH infection, but overall weaker. RSV had
190 a relatively mild inflammatory profile, the least pro-inflammatory amongst the three types of URTI,
191 which was characterized by absence of chemokine induction and a relatively weak antiviral
192 response. Despite of differences introduced due to virus type and infection time, 9 cytokines (GM-
193 CSF, Granzyme A, IFN-g, IL-2, IL33, IL-4, IL10, IL-6 and TNF-a) were identified as commonly induced in
194 all asymptomatic URTIs. Inflammatory responses per group were also stratified and analysed based

195 on the pneumococcal carriage outcome after experimental challenge to investigate whether certain
196 inflammatory mediators are associated with susceptibility to Spn carriage acquisition. In the studied
197 cohort, there was no differentially expressed cytokines between those that would become colonised
198 and those aborted colonisation in each viral group separately or in the combined viral infected
199 groups (data not shown).

200 **Route of bacterial shedding and association with colonising density**

201 In a subset (n=169) of participants (all individuals enrolled into two consecutive studies from 2018 to
202 2019) we investigated bacterial shedding through the mouth and nose collecting cough and nose-to-
203 hand samples (Suppl. Figure 1), irrespective of the carriage outcome. Bacterial shedding by any route
204 required successful colonisation after the bacterial challenge at D0. None of the non-colonised
205 individuals (n=48) had a positive shedding sample. Amongst the Spn-colonised (n=121), we identified
206 47 Spn-shedders, who shed bacterial via the nose and/or mouth at any time point post challenge
207 and 74 non-shedders. In the Spn-shedders group, 64% (30/47) expired bacterial via the nose (nose-
208 shedders), 32% (15/47) via the mouth while coughing (cough-shedders) and only 4% (2/47) via both
209 routes simultaneously (Figure 3A). Bacterial colonising density was consistently higher in the nose-
210 shedders compared to non-shedders group (Figure 3B). Further analysis of bacterial shedding in
211 association with bacterial colonising density revealed a differential profile for cough- and nose-
212 shedders. A gradual increase in the proportion of nose-shedders was observed when bacterial
213 density increased, reaching 80 and 80% in the highest density increments (10^4 - 10^5 and 10^5 - 10^6
214 CFU/ml of NW, respectively) (Figure 3C and Table 3). In addition, the number of expired bacteria via
215 the nose (shedding density) at any time point was strongly correlated with the nasal bacterial
216 density (Figure 3D) ($R=0.52$, $p=0.0004$). Contrarily, cough-shedding was not influenced by
217 fluctuations in nasal bacterial density, as the proportion of cough-shedders remained relatively low
218 in all density increments (Figure 3C and Table 3). This differential pattern was also observed in
219 relation to time post inoculation. Nose-shedders tended to shed bacteria predominately at D2 (72%,
220 23/32) and D6 (60%, 19/32) post inoculation; time points with highest mean densities (Figure 3F),
221 whereas shedding via cough was occurred evenly across time points (Figure 3E-F).

222 We also investigated the contribution of respiratory viruses in bacterial shedding, due to previously
223 observed associations with density changes and induction of nasal inflammatory responses.
224 Coronaviruses was detected only in the non-shedders group in a proportion of 8% (6/74), rhinovirus
225 was found in similar proportion in shedders and non-shedders, whereas RSV and HPIVs was detected
226 in a small proportion (3%, 1/30) of nose-shedders only. There was no difference in viral copies
227 detected in Spn-shedders and non-shedders (Suppl. Figure 4A). However, Spn-shedders with

228 asymptomatic URTI had substantially higher bacterial colonising density at D2, D6 and D16 post
229 inoculation compared to non-shedders with (Suppl. Figure 4B). The small numbers of individuals
230 with confirmed asymptomatic URT and shedding data limited further investigation of the role of viral
231 infection in shedding.

232 **Distinct nasal cell profile and gene expression patterns in nose-shedders**

233 We next analysed the cellular composition of nasal cells obtained by nasal microbiopsies, applying
234 flow cytometry. The number of leukocytes, granulocytes and monocytes was expressed as a ratio to
235 epithelial cells [20] and compared between the three Spn-colonised groups at baseline, day2, day6
236 and day16 post pneumococcal challenge (Figure 4A). At baseline, overall levels of nasal immune cells
237 were comparable amongst the groups, with the exception of CD8⁺ T cells levels (Figure 4A). After
238 challenge, nose-shedders had a substantial increase in the proportion of neutrophils compared to
239 non-shedders and in monocytes and CD4⁺ T cells compared to both cough- and non-shedders. This
240 increase in immune cells was observed only at 2 days post challenge and only in the nose-shedders
241 group.

242 Nasal cells were also obtained from the same individuals for a parallel transcriptome analysis (Figure
243 4B). Genes transcriptional changes in cough- and nose-shedders per time point post challenge were
244 described in relation to non-shedders as the reference group. Cough-shedders had an enrichment in
245 gene sets associated with innate immune responses and cytokine signalling at the very early stages
246 of pneumococcal colonisation (day 2 PI), which was dismissed at later time points. In nose-shedders,
247 adaptive immunity gene sets and cytokines signalling were upregulated early after colonisation,
248 whereas enrichment in innate immune system gene sets was delayed (day16 PI).

249

250 **Nasal inflammation drives bacterial shedding through the nose.**

251 Nasal inflammation was also assessed by measuring the levels of 30 cytokines in the nasal fluid of
252 nose- and cough-shedders at four time points (D2, D6, D16 and D22) post-challenge and compared
253 with the levels measured in non-shedders at the same time points. Nose-shedders had a distinct pro-
254 inflammatory profile, defined by enrichment in growth factors, pro-inflammatory cytokines (IL-1b
255 and TNFa) and chemokines that affect monocytes and granulocytes migration, such as macrophage-
256 inflammatory protein-1a and -1b (MIP-1a, MIP-1b) and granulocyte-colony stimulation factor (G-
257 CSF). This increase in nasal inflammatory responses compared to non-shedders group was observed
258 at D2 (upregulation of 9 out of 30 cytokines), D6 and D16 (upregulation of 7 out of 30 cytokines) but
259 not at D22 post-challenge. On the other hand, cough-shedders did not differ from their non-shedder

260 counterparts at any time point over the course of experimentally induced pneumococcal
261 colonisation.

262 Acute nasal inflammation was identified as a key characteristic of nasal bacterial shedding, as in the
263 case of pneumococcal density. To dissect the associations between nasal inflammatory responses,
264 bacterial colonising density and bacterial shedding, these parameters were analysed using
265 correlation plots for the time points wherein bacterial shedding was more frequently observed (D2
266 and D6 post-infection). Notably, correlation plots indicated a positive association between nasal
267 inflammatory responses and bacterial shedding through the nose. At day 2 post-challenge, the
268 association with inflammatory responses included pro-inflammatory cytokines (IL-6, TNF α , IL-1RA)
269 and the involvement of several monocyte and granulocytes chemokines and growth factors
270 [monocyte-chemoattractant protein-1 (MCP-1), MIP-1a, MIP-1b, MIG and granulocyte-monocyte
271 colony stimulation factor (GM-CSF)] (Figure 5C), whereas at day 6 associations were restricted to
272 only 2 pro-inflammatory cytokines (IL-6 and TNF α) (Figure 5D). A similar relationship was also
273 observed between nasal inflammation and pneumococcal density, deriving mainly from pro-
274 inflammatory responses and MCP-1 chemokine at Day 2 (Figure 5C) and was enriched with
275 additional chemoattract cytokines (MIP-1a, MIP-1b, RANTES) at Day 6 post-challenge (Figure 5D).

276 **DISCUSSION**

277 In humans, respiratory viral and pneumococcal co-infections have mainly been studied in the
278 context of disease (hospitalisation cases, pathogenicity) [10, 38] describing associations rather than
279 a causative relationship. How respiratory viruses influence pneumococcal carriage acquisition,
280 leading to subsequent disease and bacterial transmission to the community, is not well described.

281 Here, we investigated the impact of natural viral URTI on acquisition of experimentally induced
282 colonisation and have shown that primary infection with certain respiratory viruses, such as
283 rhinovirus, RSV, PIVs, but not seasonal coronaviruses, increased pneumococcal carriage rates. In
284 agreement with previous reports[39, 40], presence of these respiratory viruses in the upper airways
285 also led to higher pneumococcal colonising density, with RSV infection having the most striking
286 effect. It is possible that viral infection and subsequent inflammation provide an environment,
287 enriched in nutrients, promoting bacterial proliferation [41].

288 Our results support epidemiological and clinical evidence, suggesting that certain respiratory viruses,
289 may have a substantial role in the burden of pneumococcal disease [8, 9, 38, 42-44]. A newly
290 acquired carriage episode poses an increased risk towards disease development, likely because the
291 host has not yet developed immunity to the pathogen[45, 46]. Hence, a viral-induced pneumococcal

292 colonisation episode, which commences with high colonisation density, could trigger disease
293 development, particularly in the at-risk populations, such as the very young, the old and the
294 immunocompromised.

295 RSV significant contribution to paediatric IPDs was recently highlighted by two surveillance studies
296 conducted in Israel[8] and France[9] during implementation of non-pharmaceutical interventions
297 early in COVID-19 pandemic. Both studies reported that the overall prevalence of pneumococcal
298 carriage in paediatrics was not significantly altered. This could be a result of population recruitment,
299 study set-up and time of pneumococcal infection. Our study included healthy non-colonised adults,
300 who were experimentally exposed to pneumococcus at a known time, whereas the Israel and French
301 studies were both pneumococcal colonisation and IPD surveillance studies in children. RSV also has
302 been linked with increased pneumococcal invasiveness. Epidemiological data have reported
303 increased frequency of less invasive, non-vaccine included, pneumococcal serotypes (15B/C, 33F),
304 during RSV infection in paediatric cases of community-acquired alveolar pneumonia [47]

305 On the other hand, there are conflicting data on the relationship between rhinovirus and
306 parainfluenza infection and pneumococcal disease[8, 38, 39]. The balance shifts depending on the
307 reported population, as those viral infections commonly associate with pneumococcal disease in
308 asthmatics, HIV infected individuals and the elderly[38]. However, rhinoviral infection is very
309 common amongst children and causes rhinitis[48], which in turn can lead to increased nasal
310 inflammation, and hence pneumococcal shedding and onwards transmission during co-infection.

311 We also examined bacterial shedding through the nasal and oral route during experimentally
312 induced pneumococcal carriage. We have showed that pneumococci exit the host more frequently
313 via the nose, early after establishment of colonisation, predominantly when the nasopharynx is
314 inflamed and colonised with high bacterial load (Figure 6). In animal models, modulation of nasal
315 inflammation alters pneumococcal shedding and transmission rates, indicating a direct relationship
316 of positive association[19, 49]. Pneumolysin, a toxin produced and secreted by pneumococci, has
317 also been reported as a significant factor that promotes inflammation and subsequently increased
318 bacterial shedding[49]. Our results suggest that nasal shedding is more likely to occur during the
319 early stages of a colonisation episode, when host innate immune responses, such as local
320 inflammation, neutrophils degranulation and phagocytes recruitment are at their peaks, as
321 previously observed in the human challenge model[20, 50]. An inflamed nasal mucosa can lead to
322 increased volume and flow of secretions locally, promoting shedding and prolonged pneumococcal
323 survival in the environment [6, 49]. On the other hand, cough-induced shedding was dissociated
324 from host responses and bacterial density (Figure 6), allows to speculate that this route of shedding

325 is more common in older adults, wherein pneumococci can be more frequently detected in the
326 throat and oral cavity. In this study any association between viral URLT and bacterial shedding was
327 prohibited by the low numbers of viral-infected individuals in the nested shedding study, although
328 rhinoviral URLT was well represented in the shedders group. Also, viral-infected shedders were
329 colonised with higher pneumococcal density compared to their non-shedder counterparts. Our
330 findings suggest that pneumococcal colonised adults, even when asymptomatic, may be a source of
331 contagion, particularly when are heavily colonised, as in the case of viral co-infection.

332 Our study has limitations. Viral URTIs were naturally acquired and assessed by molecular methods
333 only before challenge, and hence co-infection with pneumococcus may had occurred at any time
334 point through the course of the primary viral infection. In addition, only individuals with
335 asymptomatic URTI were enrolled into the challenge studies, as per studies inclusion/exclusion
336 criteria. The non-specified time of viral infection onset and the lack of symptoms may have masked
337 viral-induced nasal inflammation and the optimum effect that certain respiratory viruses have on
338 carriage acquisition. However, our results reflect some of the viral-pneumococcal associations
339 described in large epidemiological studies, as in the case of highly influential RSV[8, 10, 51, 52] and
340 the ambiguous contribution of seasonal coronaviruses in secondary pneumococcal diseases [53, 54].
341 Another limitation arises from the monomeric use of only pneumococcal serotype 6B, as challenge
342 agent. Further studies are needed to investigate whether viral-pneumococcal relationship is
343 serotype dependent and whether during colonisation with other pneumococcal serotypes, the
344 bacterial exhibit the similar or differential pattern of shedding. Another limitation is that we only
345 investigated one direction of viral-bacterial relationship, with virus infection coming first. Further
346 studies are needed to investigate the effects of a concurrent virus infection in an established
347 colonisation episode as well as how pneumococcus can impact on subsequent virus infections and
348 host responses.

349 The findings of this study suggest that protection against respiratory viral infections and control of
350 pneumococcal density would have a major contribution in preventing pneumococcal disease and
351 blocking bacterial transmission. Vaccine interventions have the potential to confer this dual
352 outcome. Current licenced pneumococcal conjugate vaccines have undoubtedly reduced IPD
353 cases[55], but their effect on pneumococcal colonisation density has been underestimated. Control
354 of pneumococcal density by PCVs, as shown in experimentally colonised adults[56], can play a
355 pivotal role in preventing pneumococcal disease and reducing pneumococcal transmission. Yet, PCVs
356 protect against a limited number of the most invasive serotypes. After interaction with certain
357 viruses, less invasive, non-vaccine serotypes may exhibit heightened ability to invade or exit the
358 human host. In this occasion, viral vaccines, may further contribute to the reduction of

359 pneumococcal disease burden and onwards transmission as an additional benefit beyond the virus-
360 specific direct protection.

361 **Acknowledgments**

362 We thank all the patients and healthy volunteers who participated in the present study and all the
363 clinical staff who helped with recruitment and sample collection. The study was financially
364 supported by the Bill and Melinda Gates Foundation (grant no. OPP1117728) and the UK Medical
365 Research Council (grant no. M011569/1) awarded to D.M.F and S.B.G. and a Robert Austrian
366 Research award awarded to E.M.

367 **Authors Contribution**

368 E.M and D.M.F conceived and designed the study. H.H, A.H.W., M.F., R.R and A.M.C. recruited,
369 consented study participants and obtained human samples. E.N, A.B, A.H, J.R, F.E and C.S processed
370 samples. E.M, E.N., A.G, J.R and D.B generated and analysed the data.

371 E.M., A.G. and D.M.F interpreted data. E.M. wrote the manuscript and with subsequent inputs from
372 the co-authors. All co-authors approved the final version of the manuscript.

373

374

375 **References**

- 376 1. Almeida ST, Paulo AC, Froes F, de Lencastre H, Sa-Leao R. Dynamics of Pneumococcal
377 Carriage in Adults: A New Look at an Old Paradigm. *J Infect Dis.* 2021;223(9):1590-600. Epub
378 2020/09/03. doi: 10.1093/infdis/jiaa558. PubMed PMID: 32877517.
- 379 2. Smith EL, Wheeler I, Adler H, Ferreira DM, Sa-Leao R, Abdullahi O, et al. Upper airways
380 colonisation of *Streptococcus pneumoniae* in adults aged 60 years and older: A systematic review of
381 prevalence and individual participant data meta-analysis of risk factors. *J Infect.* 2020;81(4):540-8.
382 Epub 2020/06/21. doi: 10.1016/j.jinf.2020.06.028. PubMed PMID: 32562794; PubMed Central
383 PMCID: PMC7532703.
- 384 3. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, et al. Nasopharyngeal
385 Carriage of *Streptococcus pneumoniae* by Adults and Children in Community and Family Settings.
386 *Clinical Infectious Diseases.* 2004;38(5):632-9. doi: 10.1086/381547.
- 387 4. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et al. Carriage of *Streptococcus*
388 *pneumoniae* and other respiratory bacterial pathogens in low and lower-middle income countries: a
389 systematic review and meta-analysis. *PLoS One.* 2014;9(8):e103293. doi:
390 10.1371/journal.pone.0103293. PubMed PMID: 25084351; PubMed Central PMCID:
391 PMC4118866.
- 392 5. Bogaert D, De Groot R, Hermans PW. *Streptococcus pneumoniae* colonisation: the key to
393 pneumococcal disease. *Lancet Infect Dis.* 2004;4(3):144-54. doi: 10.1016/S1473-3099(04)00938-7.
394 PubMed PMID: 14998500.

- 395 6. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization
396 and invasion. *Nat Rev Microbiol*. 2018;16(6):355-67. doi: 10.1038/s41579-018-0001-8. PubMed
397 PMID: 29599457; PubMed Central PMCID: PMC5949087.
- 398 7. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental link
399 between pneumococcal carriage and disease. *Expert Rev Vaccines*. 2012;11(7):841-55. doi:
400 10.1586/erv.12.53. PubMed PMID: 22913260.
- 401 8. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline
402 in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19)
403 Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent
404 Pneumococcal Carriage: A Prospective Cohort Study. *Clin Infect Dis*. 2022;75(1):e1154-e64. Epub
405 2021/12/15. doi: 10.1093/cid/ciab1014. PubMed PMID: 34904635; PubMed Central PMCID:
406 PMC5949087.
- 407 9. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, et al. Association of
408 Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococcal
409 Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. *JAMA*
410 *Netw Open*. 2022;5(6):e2218959. Epub 2022/06/29. doi: 10.1001/jamanetworkopen.2022.18959.
411 PubMed PMID: 35763298; PubMed Central PMCID: PMC9240903.
- 412 10. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between
413 respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US
414 hospitalization data. *PLoS Med*. 2015;12(1):e1001776. Epub 2015/01/07. doi:
415 10.1371/journal.pmed.1001776. PubMed PMID: 25562317; PubMed Central PMCID:
416 PMC4285401.
- 417 11. Hernandez S, Munoz-Almagro C, Ciruela P, Soldevila N, Izquierdo C, Codina MG, et al.
418 Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13
419 Vaccination in Pandemic and Nonpandemic Influenza Periods. *J Clin Microbiol*. 2019;57(8). Epub
420 2019/06/14. doi: 10.1128/JCM.00363-19. PubMed PMID: 31189583; PubMed Central PMCID:
421 PMC6663900.
- 422 12. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the lungs
423 of mice following primary respiratory syncytial virus infection. *J Med Virol*. 2006;78(6):829-38. doi:
424 10.1002/jmv.20631. PubMed PMID: 16628585.
- 425 13. Smith CM, Sandrini S, Datta S, Freestone P, Shafeeq S, Radhakrishnan P, et al. Respiratory
426 syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin binding
427 protein 1a. A new paradigm in respiratory infection. *Am J Respir Crit Care Med*. 2014;190(2):196-
428 207. doi: 10.1164/rccm.201311-2110OC. PubMed PMID: 24941423; PubMed Central PMCID:
429 PMC4226051.
- 430 14. Levine H, Zarka S, Dagan R, Sela T, Rozhavski V, Cohen DJ, et al. Transmission of
431 Streptococcus pneumoniae in adults may occur through saliva. *Epidemiol Infect*. 2012;140(3):561-5.
432 Epub 2011/06/17. doi: 10.1017/S0950268811000884. PubMed PMID: 21676361.
- 433 15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage
434 of Streptococcus pneumoniae among their younger siblings. *Pediatr Infect Dis J*. 2003;22(6):524-32.
435 Epub 2003/06/12. doi: 10.1097/01.inf.0000069760.65826.f2. PubMed PMID: 12799509.
- 436 16. Zangari T, Ortigoza MB, Lokken-Toyli KL, Weiser JN. Type I Interferon Signaling Is a Common
437 Factor Driving Streptococcus pneumoniae and Influenza A Virus Shedding and Transmission. *mBio*.
438 2021;12(1). Epub 2021/02/18. doi: 10.1128/mBio.03589-20. PubMed PMID: 33593970; PubMed
439 Central PMCID: PMC8545127.
- 440 17. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. Influenza
441 enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in
442 ferrets. *J Infect Dis*. 2010;202(8):1287-95. doi: 10.1086/656333. PubMed PMID: 20822454; PubMed
443 Central PMCID: PMC3249639.

- 444 18. Diavatopoulos DA, Short KR, Price JT, Wilksch JJ, Brown LE, Briles DE, et al. Influenza A virus
445 facilitates *Streptococcus pneumoniae* transmission and disease. *FASEB J*. 2010;24(6):1789-98. Epub
446 2010/01/26. doi: 10.1096/fj.09-146779. PubMed PMID: 20097876.
- 447 19. Richard AL, Siegel SJ, Erikson J, Weiser JN. TLR2 signaling decreases transmission of
448 *Streptococcus pneumoniae* by limiting bacterial shedding in an infant mouse Influenza A co-infection
449 model. *PLoS Pathog*. 2014;10(8):e1004339. Epub 2014/08/29. doi: 10.1371/journal.ppat.1004339.
450 PubMed PMID: 25166617; PubMed Central PMCID: PMC4148449.
- 451 20. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation induced
452 by influenza virus impairs human innate immune control of pneumococcus. *Nat Immunol*.
453 2018;19(12):1299-308. doi: 10.1038/s41590-018-0231-y. PubMed PMID: 30374129; PubMed Central
454 PMCID: PMC6241853.
- 455 21. Thors V, Christensen H, Morales-Aza B, Vipond I, Muir P, Finn A. The Effects of Live
456 Attenuated Influenza Vaccine on Nasopharyngeal Bacteria in Healthy 2 to 4 Year Olds. A Randomized
457 Controlled Trial. *Am J Respir Crit Care Med*. 2016;193(12):1401-9. Epub 2016/01/08. doi:
458 10.1164/rccm.201510-2000OC. PubMed PMID: 26742001; PubMed Central PMCID:
459 PMC4910891.
- 460 22. Rodrigues F, Foster D, Nicoli E, Trotter C, Vipond B, Muir P, et al. Relationships between
461 rhinitis symptoms, respiratory viral infections and nasopharyngeal colonization with *Streptococcus*
462 *pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus* in children attending daycare.
463 *Pediatr Infect Dis J*. 2013;32(3):227-32. doi: 10.1097/INF.0b013e31827687fc. PubMed PMID:
464 23558321.
- 465 23. Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, et al.
466 Experimental human pneumococcal carriage. *J Vis Exp*. 2013;(72). doi: 10.3791/50115. PubMed
467 PMID: 23439027; PubMed Central PMCID: PMC3601207.
- 468 24. Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, et al. First Human
469 Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial. *Am J*
470 *Respir Crit Care Med*. 2015. doi: 10.1164/rccm.201503-0542OC. PubMed PMID: 26114410.
- 471 25. Mitsi E, Carniel B, Reine J, Rylance J, Zaidi S, Soares-Schanoski A, et al. Nasal Pneumococcal
472 Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage
473 Responsiveness to Bacterial Pathogens. *Am J Respir Crit Care Med*. 2020;201(3):335-47. Epub
474 2019/10/19. doi: 10.1164/rccm.201903-0607OC. PubMed PMID: 31626559; PubMed Central PMCID:
475 PMC6999099.
- 476 26. Tarrago D, Fenoll A, Sanchez-Tatay D, Arroyo LA, Munoz-Almagro C, Esteva C, et al.
477 Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time
478 PCR. *Clin Microbiol Infect*. 2008;14(9):828-34. doi: 10.1111/j.1469-0691.2008.02028.x. PubMed
479 PMID: 18844683.
- 480 27. Connor V, German E, Pojar S, Mitsi E, Hales C, Nikolaou E, et al. Hands are vehicles for
481 transmission of *Streptococcus pneumoniae* in novel controlled human infection study.
482 *European Respiratory Journal*. 2018;52(4):1800599. doi: 10.1183/13993003.00599-2018.
- 483 28. de Steenhuijsen Piters WAA, Jochems SP, Mitsi E, Rylance J, Pojar S, Nikolaou E, et al.
484 Interaction between the nasal microbiota and *S. pneumoniae* in the context of live-attenuated
485 influenza vaccine. *Nat Commun*. 2019;10(1):2981. doi: 10.1038/s41467-019-10814-9. PubMed
486 PMID: 31278315; PubMed Central PMCID: PMC6611866.
- 487 29. Jochems SP, Piddock K, Rylance J, Adler H, Carniel BF, Collins A, et al. Novel Analysis of
488 Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune
489 Populations, and Superior Cytokine Detection Compared to Nasal Wash. *PLoS One*.
490 2017;12(1):e0169805. doi: 10.1371/journal.pone.0169805. PubMed PMID: 28107457; PubMed
491 Central PMCID: PMC5249128.
- 492 30. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal
493 RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21. Epub 2012/10/30. doi:

- 494 10.1093/bioinformatics/bts635. PubMed PMID: 23104886; PubMed Central PMCID:
495 PMCPMC3530905.
- 496 31. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning
497 sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923-30. Epub 2013/11/15. doi:
498 10.1093/bioinformatics/btt656. PubMed PMID: 24227677.
- 499 32. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016.
500 *Nucleic Acids Res*. 2016;44(D1):D710-6. Epub 2015/12/22. doi: 10.1093/nar/gkv1157. PubMed
501 PMID: 26687719; PubMed Central PMCID: PMCPMC4702834.
- 502 33. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
503 seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed
504 PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.
- 505 34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set
506 enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
507 *Proc Natl Acad Sci U S A*. 2005;102(43):15545-50. Epub 2005/10/04. doi: 10.1073/pnas.0506580102.
508 PubMed PMID: 16199517; PubMed Central PMCID: PMCPMC1239896.
- 509 35. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set
510 enrichment analysis. *bioRxiv*. 2021:060012. doi: 10.1101/060012.
- 511 36. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway
512 knowledgebase. *Nucleic Acids Research*. 2019;48(D1):D498-D503. doi: 10.1093/nar/gkz1031.
- 513 37. Cheliotis KS, Jewell CP, Solorzano C, Urban B, Collins AM, Mitsi E, et al. Influence of sex,
514 season and environmental air quality on experimental human pneumococcal carriage acquisition: a
515 retrospective cohort analysis. *ERJ Open Res*. 2022;8(2). Epub 2022/04/14. doi:
516 10.1183/23120541.00586-2021. PubMed PMID: 35415189; PubMed Central PMCID:
517 PMCPMC8995542 manuscript from K.S. Cheliotis (PhD student writing; no payments received
518 directly) and D.M. Ferreira (unfunded collaborator); grants or contracts received from MRC (DRUM
519 and JUNIPER Consortia) EPSRC (Bayes4Health programme and COVID-19 stochastic modelling grants,
520 NERC (COVID-19 wastewater monitoring), The Dogs Trust (clinical disease surveillance grant), BBSRC
521 (EEID elimination of disease grant) and the Wellcome Trust (GEM software grant), outside the
522 submitted work; and participation on the ONS Covid Infection Survey Advisory Board (unfunded) and
523 SPI-M-O Covid Modelling Subcommittee (unfunded), outside the submitted work. B. Urban reports
524 grants or contracts from EDCTP, Royal Society and Pfizer, outside the submitted work; and is an
525 Inner Board Member of the Irish Research Council. A.M. Collins reports receiving grants or contracts
526 from Sanofi, Pfizer and Unilever, outside the submitted work; consulting fees received from Sanofi,
527 outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus,
528 manuscript writing or educational events received from Pfizer, GSK and MSD, outside the submitted
529 work; support for attending meetings and/or travel received from GSK, outside the submitted work;
530 and participation on a data safety monitoring or advisory board for Neisseria for S'ton UK, outside
531 the submitted work. E. Nikolaou reports grants or contracts from Sanofi, the LSTM and Wellcome
532 Trust Director's catalyst fund, outside the submitted work. J. Rylance reports grants or contracts
533 received from Wellcome Trust and NIHR, outside the submitted work; consulting fees received from
534 Sanofi, outside the submitted work; and participation on the "Preventing Pneumo" trial steering
535 committee. D.M. Ferreira reports support for the present manuscript from MRC grant
536 MR/M011569/1, and Bill and Melinda Gates Foundation OPP1117728; grants or contracts received
537 from Pfizer, MSD and Sanofi, outside the submitted work; and membership of the Human Infection
538 Challenge Network for Vaccine Development and the BactiVac network (Accelerating Bacterial
539 Vaccines). The remaining authors have nothing to disclose.
- 540 38. Cilloniz C, Pericas JM, Rojas JR, Torres A. Severe Infections Due to Respiratory Viruses. *Semin*
541 *Respir Crit Care Med*. 2022;43(1):60-74. Epub 2022/02/17. doi: 10.1055/s-0041-1740982. PubMed
542 PMID: 35172359.
- 543 39. Wolter N, Tempia S, Cohen C, Madhi SA, Venter M, Moyes J, et al. High nasopharyngeal
544 pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal

- 545 pneumonia. *J Infect Dis.* 2014;210(10):1649-57. Epub 2014/06/08. doi: 10.1093/infdis/jiu326.
546 PubMed PMID: 24907383.
- 547 40. Esposito S, Zampiero A, Terranova L, Ierardi V, Ascolese B, Daleno C, et al. Pneumococcal
548 bacterial load colonization as a marker of mixed infection in children with alveolar community-
549 acquired pneumonia and respiratory syncytial virus or rhinovirus infection. *Pediatr Infect Dis J.*
550 2013;32(11):1199-204. Epub 2013/06/08. doi: 10.1097/INF.0b013e31829ec274. PubMed PMID:
551 23743541.
- 552 41. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during
553 coinfection by providing host sialylated substrates as a nutrient source. *Cell Host Microbe.*
554 2014;16(1):55-67. Epub 2014/07/11. doi: 10.1016/j.chom.2014.06.005. PubMed PMID: 25011108;
555 PubMed Central PMCID: PMC4096718.
- 556 42. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Seasonality
557 of invasive pneumococcal disease: temporal relation to documented influenza and respiratory
558 syncytial viral circulation. *Am J Med.* 2005;118(3):285-91. Epub 2005/03/05. doi:
559 10.1016/j.amjmed.2004.09.016. PubMed PMID: 15745727.
- 560 43. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, et al. Association of
561 Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococcal
562 Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. *JAMA*
563 *Network Open.* 2022;5(6):e2218959-e. doi: 10.1001/jamanetworkopen.2022.18959.
- 564 44. Madhi SA, Klugman KP, Vaccine Trialist G. A role for *Streptococcus pneumoniae* in virus-
565 associated pneumonia. *Nat Med.* 2004;10(8):811-3. Epub 2004/07/13. doi: 10.1038/nm1077.
566 PubMed PMID: 15247911; PubMed Central PMCID: PMC7095883.
- 567 45. Ghaffar F, Friedland IR, McCracken GH, Jr. Dynamics of nasopharyngeal colonization by
568 *Streptococcus pneumoniae*. *Pediatr Infect Dis J.* 1999;18(7):638-46. doi: 10.1097/00006454-
569 199907000-00016. PubMed PMID: 10440444.
- 570 46. Robinson J. Colonization and infection of the respiratory tract: What do we know? *Paediatr*
571 *Child Health.* 2004;9(1):21-4. doi: 10.1093/pch/9.1.21. PubMed PMID: 19654976; PubMed Central
572 PMCID: PMC2719511.
- 573 47. Greenberg D, Givon-Lavi N, Faingelernt Y, Ben-Shimol S, Avni YS, Bar-Ziv J, et al.
574 Nasopharyngeal Pneumococcal Carriage During Childhood Community-Acquired Alveolar
575 Pneumonia: Relationship Between Specific Serotypes and Coinfecting Viruses. *J Infect Dis.*
576 2017;215(7):1111-6. Epub 2016/12/25. doi: 10.1093/infdis/jiw613. PubMed PMID: 28011920.
- 577 48. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, et al.
578 Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. *Pediatr Allergy*
579 *Immunol.* 2003;14(5):363-70. Epub 2003/12/04. doi: 10.1034/j.1399-3038.2003.00064.x. PubMed
580 PMID: 14641606; PubMed Central PMCID: PMC7168036.
- 581 49. Zafar MA, Wang Y, Hamaguchi S, Weiser JN. Host-to-Host Transmission of *Streptococcus*
582 *pneumoniae* Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell Host Microbe.* 2017;21(1):73-83.
583 doi: 10.1016/j.chom.2016.12.005. PubMed PMID: 28081446; PubMed Central PMCID:
584 PMC5267320.
- 585 50. Carniel BF, Marcon F, Rylance J, German EL, Zaidi S, Reine J, et al. Pneumococcal colonization
586 impairs mucosal immune responses to live attenuated influenza vaccine. *JCI Insight.* 2021;6(4). Epub
587 2021/01/27. doi: 10.1172/jci.insight.141088. PubMed PMID: 33497364; PubMed Central PMCID:
588 PMC7934923.
- 589 51. Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, et al.
590 Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity.
591 *Clin Infect Dis.* 2014;58(2):188-94. doi: 10.1093/cid/cit721. PubMed PMID: 24190895; PubMed
592 Central PMCID: PMC3871795.
- 593 52. Dagan R, van der Beek BA, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger DM, et
594 al. The COVID-19 pandemic as an opportunity for unravelling the causative association between
595 respiratory viruses and pneumococcus-associated disease in young children: a prospective study.

596 EBioMedicine. 2023;90:104493. Epub 2023/03/02. doi: 10.1016/j.ebiom.2023.104493. PubMed
 597 PMID: 36857965; PubMed Central PMCID: PMCPMC9970381.
 598 53. de Koff EM, van Houten MA, Sanders EAM, Bogaert D. Severity of Respiratory Infections
 599 With Seasonal Coronavirus Is Associated With Viral and Bacterial Coinfections. *Pediatr Infect Dis J*.
 600 2021;40(1):e36-e9. Epub 2020/10/13. doi: 10.1097/INF.0000000000002940. PubMed PMID:
 601 33044434.
 602 54. Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jodar L, et al. Prevention of COVID-
 603 19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between
 604 *Streptococcus pneumoniae* and SARS-CoV-2 in the respiratory tract. *J Infect Dis*. 2021. Epub
 605 2021/03/12. doi: 10.1093/infdis/jiab128. PubMed PMID: 33693636; PubMed Central PMCID:
 606 PMCPMC7989304.
 607 55. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines
 608 on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on
 609 indirect effects. *Vaccine*. 2013;32(1):133-45. Epub 2013/05/21. doi: 10.1016/j.vaccine.2013.05.005.
 610 PubMed PMID: 23684824.
 611 56. German EL, Solorzano C, Sunny S, Dunne F, Gritzfeld JF, Mitsi E, et al. Protective effect of PCV
 612 vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling
 613 colonisation density. *Vaccine*. 2019;37(30):3953-6. Epub 2019/06/10. doi:
 614 10.1016/j.vaccine.2019.05.080. PubMed PMID: 31176540; PubMed Central PMCID:
 615 PMCPMC6611220.

Table 1: Characteristics of study participants

	Uninfected (n=482)	Asymptomatic URTI (n=99)				
Age in years						
Median and IQR	21 (19-22)	21 (19-22)				
Gender						
Male (%)	39% (188/482)	42% (42/99)				
Pneumococcal Carriage (%)						
Experimental carriage acquisition	49% (235/482)	57% (56/99)				
Viral Infection	N/A	RH (n=44)	HCoVs (N=25)	RSV (n=8)	HPIVs (n=7)	Others (n=15)
Viral strains detected			NL63, HKU1, OC43 & 229E	RSV-A & RSV-B		Adenovirus=4 Bocavirus= 4 Enterovirus=3 HMPV= 2 Influenza A/B=2
Male (%)		17 (39%)	11 (44%)	4 (50%)	4 (57%)	6 (40%)
Experimental Carriers (%)		29 (66%)	11 (44%)	7 (88%)	5 (71%)	4 (27%)
Odds Ratio (95% CI)						

Table 2: 6B Pneumococcal colonisation status assessed according to viral infection and type of virus.

Virus	N of colonised/ Total N (%)		Odds Ratio (95% CI)	P value
	Virus infected	Non-infected		
All viruses	56/99 (57%)	235/428 (49%)	1.37 (0.88 – 2.11)	0.185
RH	29/44 (66%)	235/428 (49%)	2.03 (1.09 – 3.80)	0.035
HCoV	11/25 (44%)	235/428 (49%)	0.83 (0.37 – 1.78)	0.55
RSV	7/8 (88%)	235/428 (49%)	5.26 (0.90 – 30.6)	0.034
PIV	5/7 (71%)	235/428 (49%)	2.63 (0.56 – 13.3)	0.26

Table 3: Percentage of cough- and nose-shedders per density increment.

Density- Incremental breaks (CFU/ml of NW)	Cough-Shedder	Nose-Shedder	p-value
$<10^1$	8.7% (5/57)	0% (0/57)	0.057
$10^1 - 10^2$	5.7% (4/70)	4.3% (3/70)	>0.99
$10^2 - 10^3$	12.5% (6/48)	23% (11/48)	0.284
$10^3 - 10^4$	13% (3/23)	30.5% (7/23)	0.283
$10^4 - 10^5$	0% (0/20)	80% (16/20)	<0.0001
$10^5 - 10^6$	12.5% (1/8)	88% (7/8)	<0.01

Figure 1. Presence of asymptomatic upper airway viral infection influences pneumococcal carriage acquisition and bacterial density. **A)** Percentages of respiratory viruses detected in the upper airways of 581 healthy adults at baseline (prior to pneumococcal challenge). Differential distribution of respiratory viruses detected in those who did not become colonised (n=290, Spn- group) and those who became colonised (n=291, Spn+ group). **B)** Percentages of pneumococcal colonisation achieved after experimental challenge in the virus negative (n=482) and virus-positive group (n=99). **C)** Percentages of experimental pneumococcal colonisation achieved after challenge in those with primary asymptomatic seasonal coronavirus (HCoV) infection (11 Spn+ out of 25, p=0.55), rhinovirus (RH) infection (29 Spn+ out of 44, p=0.035), parainfluenza virus (HPIVs) infection (5 Spn+ out of 7,

p=0.25) and respiratory syncytial virus (RSV) infection (7 Spn+ out of 8, p=0.034). **D-G**) Density dynamics after pneumococcal inoculation were calculated from classical microbiology ($\log_{10}[\text{cfu/ml} + 1]$). **D**) Area under the curve (AUC) of density per time interval from day2 to day14 post inoculation with Spn6B in virus negative (n=208) and virus positive (n=43) individuals. **E-G**) Mean \pm SEM of pneumococcal density in colonised individuals for each time point after inoculation in those who had primary asymptomatic viral infection with seasonal coronavirus (HCoV, red) or rhinovirus (RH, green) or RSV (purple) or no viral infection (Virus neg, grey). Statistical analysis was determined by Fisher's exact test to compare percentages (D-E) or Mann-Whitney test (F,H & I) or Kruskal-Wallis test following correction for multiple comparisons (G). p < 0.05, **p < 0.01.

Figure 2. Inflammatory profile of the human upper airway during asymptomatic URTI. **A**) Volcano plots and **B**) heatmap showing the median \log_2 fold change (FC) in the levels of 33 cytokines in the nasal wash collected at baseline from individuals with HCoV (n = 20), rhinovirus (n = 25) and RSV infection (n = 8) versus non-viral infected group (n = 20). On volcano plots the horizontal dotted line represents the cutoff of significance (adjusted p= 0.05, after False Discovery Rate correction of the p value), whereas the vertical dotted line represents a cutoff point for determining whether the levels of cytokines were higher (right, red) or lower (left, blue) compared with those of non-viral infected group. Statistical comparisons were applied between each study group and the virus negative group using the Mann-Whitney U test, followed by Benjamini-Hochberg correction for multiple testing. p < 0.05, **p < 0.01, ***p < 0.001. Nonsignif, nonsignificant; Down, downregulation; Up, upregulation.

Figure 3. Route of bacterial shedding and association with colonising density. **A**) Percentage of bacterial shedders (n=47) and non-shedders (n=74) amongst the Spn colonised individuals (top) and breakdown for route of shedding in the Spn shedders. **B**) Mean \pm SEM of nasal pneumococcal density per time point after inoculation day (D0) in Spn colonised individuals who shed bacteria through the nose (nose-shedders, n=30) or mouth while coughing (cough-shedders, n=15) or did not shed bacterial (non-shedders, n=74). **C**) Incidence of bacterial shedding for cough- and nose-shedders in association with nasal pneumococcal density expressed as \log_{10} increased increments. **D**) Correlation between nasal Spn density (CFU/ml of NW) and shedding density (CFU/ml), Linear regression line with 95% confidence interval (grey shading) are shown. **E**) Percentage of Spn-shedders who emitted bacterial via coughing or nose per each time point after spn challenge. **F**) Levels of nasal pneumococcal density measured per time point PI in cough-shedders (turquoise) and nose-shedders (purple). Data are presented as median values and interquartile ranges (IQRs). **G**) Respiratory viral infection incidence in non-shedders, nose- and cough-shedders. Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons (B), Fisher-test exact test (C) or two-tailed Spearman rank test (D). ***p < 0.001, ****p < 0.0001.

Figure 4. Distinct nasal inflammatory profile in those with asymptomatic URT infection. **A**) Volcano plots showing the median and IQR of nasal monocyte, neutrophils and T cell numbers normalised to the epithelial cell numbers in non-shedders (n=), cough-shedders (n=) and nose-shedders (n=). Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons. **B**) Gene set variance analysis (GSVA) of immune response pathways of nasal cells collected at D2, D6 and D16 after pneumococcal in cough- and nose-shedders in relation to non-

shedders colonised individuals at the same time points. Normalized enrichment score (NES) is presented in gradient colour. Red shades indicate pathways overrepresented, whereas blue shades depict the underrepresented pathways at each time point in relation to non-shedders group. Statistical differences were determined by Wilcoxon's paired test corrected by multiple-comparison testing (Benjamini-Hochberg).

Figure 5. Nasal inflammation in nose-shedders and correlation bacterial density and shedding. Heat maps showing the median \log_2 fold change (FC) in the levels of 29 cytokines and chemokines in the nasal wash samples **a)** nose-shedders (n=28) and **b)** cough-shedders (n=8) compared to non-viral infected group (n = 46) at D2, D6, D16 and D22 post challenge. Used two-tailed Mann-Whitey test, followed by Benjamini-Hochberg correction for multiple testing. **C-D)** Correlograms of nose-shedders at D2 and D6 post-challenge, respectively. Spearman rank order correlation values (R) are shown from red (-1.0) to blue (1.0); R values are indicated by colour and square size. P values are indicated by red asterisks. *p < 0.05, **p < 0.01, ***p < 0.001.




Figure 1





Figure 2




Figure 3







Figure 4


A

Nose-shedders



B

Cough-shedders



- Growth factors
- Chemokines
- Adaptive immunity
- Pro-inflammatory
- Anti-inflammatory

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.08.24302534>; this version posted February 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

C

D




Figure 5




Figure 6